Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-R8760 is a first-in-class, gallium-68-labeled small molecule radioligand imaging agent developed for the detection of adrenocortical carcinoma (ACC). It functions as a diagnostic radiopharmaceutical by selectively binding with high affinity to the melanocortin 2 receptor (MC2R), also known as the adrenocorticotropic hormone receptor, which is highly expressed on ACC cells. The agent enables PET imaging to localize and identify MC2R-expressing tumors, supporting patient selection for potential MC2R-directed therapies. Developed by Radionetics Oncology, this compound represents an innovative approach in precision oncology diagnostics for rare adrenal cancers[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-R8760.